Alembic Pharma gets USFDA nod for diabetes drug

New Delhi: Alembic Pharmaceuticals said Friday it has received tentative approval from the US health regulator to market Alogliptin and Metformin Hydrochloride tablets, an anti-diabetes medication, in the US market. The company’s product is a generic version of Takeda Pharma USA’s Kazano tablets, Alembic Pharmaceuticals said in a regulatory filing.

Alogliptin and Metformin Hydrochloride tablets had an estimated market size of USD 22.5 million in the US for 12 months ending December 2017, according to the market data.

Alembic now has a total of 77 abbreviated new drug application (ANDA) approvals from the USFDA.

Shares of the company gained 1.17 per cent to settle at Rs 647.70 apiece on BSE Friday.

  • Related Posts

    After two years, pharma volumes pick up pace

    NEW DELHI: The domestic pharmaceutical retail market is showing its strongest signs yet of a shift from price-led to demand-led growth. Volume growth crossed 3% in June, the first time…

    NPPA fixes prices of 39 drugs, raises anti-rabies immunoglobulin rate

    The National Pharmaceutical Pricing Authority (NPPA) has allowed an increase in the retail price of anti-rabies immunoglobulin while fixing the retail prices of 39 drug formulations.  According to a gazette…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    After two years, pharma volumes pick up pace

    After two years, pharma volumes pick up pace

    NPPA fixes prices of 39 drugs, raises anti-rabies immunoglobulin rate

    NPPA fixes prices of 39 drugs, raises anti-rabies immunoglobulin rate

    Tambaram police arrest two persons after seizing 1,100 banned tablets, 5 kg ganja

    Tambaram police arrest two persons after seizing 1,100 banned tablets, 5 kg ganja

    Rajasthan Healthcare Crisis: 8 Mothers Die Post-C-Section

    Rajasthan Healthcare Crisis: 8 Mothers Die Post-C-Section

    Steroid cream misuse fuels spurt in fungal infections

    Steroid cream misuse fuels spurt in fungal infections

    Dr Reddy’s delays semaglutide supplies due to API issue

    Dr Reddy’s delays semaglutide supplies due to API issue